T1 Evidence in Children

toujeo logoToujeo® is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. Discover the Toujeo® Evidence in T1DM below and get access to patient supporting tools and materials for children with T1DM who have been prescribed Toujeo®.

Randomised, Open Label Clinical Trial

Toujeo vs Insulin Glargine 100 U/mL

6 month, randomised, open label, double-arm, parallel group, non-inferiority study in 463 patients with T1DM.

Objective: To demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL (a standard of care) in change of HbA1c from baseline to Week 26 in children/adolescents aged >6 years with T1DM.

Meta Analysis

Toujeo® vs Insulin Glargine 100 U/mL

Post-hoc meta-analysis of three EDITION 6-month, Phase III, randomised clinical trials in a broad population including children aged 6+.

Post-hoc meta-analysis aim:Exploring the risk for severe hypoglycaemia with Toujeo® vs insulin glargine 100 units/mL in the pool of studied patients with T1DM.

Edition 4 (549 adults), Edition Junior (463 children), Edition JP (245 adults).

Toujeo T1 Children's Starter Pack

Download a digital starter pack which you can send digitally to your paediatric patients and their guardians to help them make a positive start with Toujeo®.

Game: Learning about diabetes with the Diabeasties

Book: Explaining diabetes to children - the Diabeasties

Monitoring diary for children

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close